How to buy Edwards Lifesciences (EW) stocks

Edwards Lifesciences is a medical devices business based in the US. Edwards Lifesciences shares (EW) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $74.81 – an increase of 2.03% over the previous week. Edwards Lifesciences employs 19,800 staff and has a trailing 12-month revenue of around $6.3 billion.

Our top picks for where to buy Edwards Lifesciences stock

Buy Edwards Lifesciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Edwards Lifesciences stock price (NYSE: EW)

Use our graph to track the performance of EW stocks over time.

Edwards Lifesciences stocks at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$74.81
52-week range	$58.93 - $96.12
50-day moving average more info button	$69.64
200-day moving average more info button	$78.52
Wall St. target price	$79.23
PE ratio more info button	28.112
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$2.59

Is it a good time to buy Edwards Lifesciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Edwards Lifesciences price performance over time

Historical closes compared with the close of $74.81 from 2024-12-20

1 week (2024-12-13)	2.03%
1 month (2024-11-22)	6.14%
3 months (2024-09-20)	11.94%
6 months (2024-06-21)	-17.70%

1 year (2023-12-22)	-1.35%
2 years (2022-12-22)	0.48%
3 years (2021-12-22)	127.83
5 years (2019-12-20)	78.7967

Is Edwards Lifesciences stock undervalued or overvalued?

Valuing Edwards Lifesciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Edwards Lifesciences's P/E ratio

Edwards Lifesciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Edwards Lifesciences shares trade at around 28x recent earnings.

That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).

Edwards Lifesciences's PEG ratio

Edwards Lifesciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.8062. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Edwards Lifesciences's EBITDA

Edwards Lifesciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.1 billion.

The EBITDA is a measure of a Edwards Lifesciences's overall financial performance and is widely used to measure a its profitability.

Edwards Lifesciences financials

Revenue TTM	$6.3 billion
Operating margin TTM	29.11%
Gross profit TTM	$4.3 billion
Return on assets TTM	10.65%
Return on equity TTM	19.14%
Profit margin	65.86%
Book value	$16.18
Market Capitalization more info button	$42.9 billion

TTM: trailing 12 months

Edwards Lifesciences stock dividends

We're not expecting Edwards Lifesciences to pay a dividend over the next 12 months.

Have Edwards Lifesciences's stocks ever split?

Edwards Lifesciences's stocks were split on a 3:1 basis on 31 May 2020 . So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences stocks – just the quantity. However, indirectly, the new 66.7% lower stock price could have impacted the market appetite for Edwards Lifesciences stocks, which in turn could have impacted Edwards Lifesciences's stock price.

Edwards Lifesciences stock price volatility

Over the last 12 months, Edwards Lifesciences's stocks have ranged in value from as little as $58.93 up to $96.12. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences's is 1.12. This would suggest that Edwards Lifesciences's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Edwards Lifesciences overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California..

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Edwards Lifesciences is owned by insiders or institutions?
Currently 0.912% of Edwards Lifesciences stocks are held by insiders and 85.886% by institutions. How many people work for Edwards Lifesciences?
Latest data suggests 19,800 work at Edwards Lifesciences. When does the fiscal year end for Edwards Lifesciences?
Edwards Lifesciences's fiscal year ends in December. Where is Edwards Lifesciences based?
Edwards Lifesciences's address is: One Edwards Way, Irvine, CA, United States, 92614 What is Edwards Lifesciences's ISIN number?
Edwards Lifesciences's international securities identification number is: US28176E1082 What is Edwards Lifesciences's CUSIP number?
Edwards Lifesciences's Committee on Uniform Securities Identification Procedures number is: 28176E108

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.